nyuuzyou/wikis huggingface dataset:
Estramustine (Emcyt)

==General information==
Class/mechanism: Nornitrogen mustard (similar to mechlorethamine) linked to estradiol. The estradiol component helps the drug to be preferentially delivered to estrogen receptor-positive cells. The mustard component serves as an alkylator and causes DNA crosslinks. Treatment may result in elevated plasma levels of estradiol.Estramustine (Emcyt) package insert Estramustine (Emcyt) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Estramustine (Emcyt) package insert
*Estramustine (Emcyt) patient drug information (Chemocare)Estramustine (Emcyt) patient drug information (Chemocare)
*Estramustine (Emcyt) patient drug information (UpToDate)Estramustine (Emcyt) patient drug information (UpToDate)
==History of changes in FDA indication==
*1981-12-24: Initial FDA approval
==History of changes in EMA indication==
*1971-09-02: EURD
==Also known as==
*Generic name: estramustine phosphate sodium
*Brand names: Emcyt, Estracit, Estram, Estramin, X-Trant
==References==
Category:Drugs
Category:Oral medications
Category:Nitrogen mustards
Category:Prostate cancer medications
Category:FDA approved in 1981
Category:EMA approved in 1971
Ethinylestradiol

Hormone replacement therapy
==Diseases for which it was used==
*Breast cancer
==History of changes in FDA indication==
*1943-06-25: Initial approval
*2004-06-04: Withdrawn at the request of the manufacturer
==Also known as==
*Generic names: EE
Category:Drugs
Category:Oral medications
Category:Breast cancer medications (historic)
Category:FDA approved in 1943
Category:FDA withdrawn in 2004
Category:Stub
Etranacogene dezaparvovec (Hemgenix)

==General information==
Class/mechanism: adeno-associated virus vector-based gene therapy (adeno-associated virus serotype 5; AAV5) which delivers a gene encoding the Padua variant of human coagulation factor IX (hFIX-Padua) and results in the recipient producing circulating Factor IX.Etranacogene dezaparvovec (Hemgenix) package insert Etranacogene dezaparvovec (Hemgenix) package insert (locally hosted backup)Hemgenix manufacturer's website
Route: IV 
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Hemophilia B
==Patient drug information==
*Etranacogene dezaparvovec (Hemgenix) package insert
*Etranacogene dezaparvovec (Hemgenix) patient drug information (UpToDate)Etranacogene dezaparvovec (Hemgenix) patient drug information (UpToDate)
==History of changes in FDA indication==
*2022-11-22: Approved for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
==History of changes in EMA indication==
*2023-02-20: Granted conditional authorisation for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.
==Also known as==
*Generic name: etranacogene dezaparvovec-drlb
==References==
Category:Drugs
Category:Intravenous medications
Category:Stub
Category:Inherited coagulopathy medications
Category:Coagulation factors
Category:EMA approved in 2023
Category:FDA approved in 2022
Category:Hematology medications
Exagamglogene autotemcel (Casgevy)

==Mechanism of action==
Gene therapy
==Diseases for which it is established==
*Beta thalassemia
*Sickle cell disease (SCD)
==History of changes in FDA indication==
*2023-12-08: Approved for the treatment of sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). (Based on CLIMB SCD-121)
*2024-01-16: Approved for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. (Based on CLIMB THAL-111)
==Also known as==
*Generic name: exa-cel
*Brand name: Casgevy
Category:Drugs
Category:Intravenous medications
Category:Gene therapy
Category:Sickle cell anemia medications
Category:Beta thalassemia medications
Category:FDA approved in 2023
Example orders for 5-FU & high-dose Leucovorin (Roswell Park regimen - HDLV) in colon cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV)==
Original references may be found at 5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV) (adjuvant) & 5-FU & high-dose Leucovorin (Roswell Park regimen/HDLV) (metastatic)
===Example regimen #1===
*Folinic acid (Leucovorin) 500 mg/m2 IV over 2 hours on days 1, 8, 15, 22, 29, 36, given first
*Fluorouracil (5-FU) 500 mg/m2 IV push on days 1, 8, 15, 22, 29, 36, 1 hour after start of leucovorin
8-week cycles x 3-4 cycles for adjuvant therapy; in metastatic settings, given until progression of disease or unacceptable toxicity
====Supportive medications====
*Prochlorperazine (Compazine) 10 mg PO once; 30 minutes prior to chemotherapy
*Ondansetron (Zofran) 8 mg IV prn nausea 
*Dexamethasone (Decadron) 10 mg IV prn nausea
Hydration:
*500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
*Hold if patient has significant diarrhea/mucositis, ANC <1000, or platelets <100 and notify physician.
Category:Example chemotherapy order sets
Example orders for 5-FU & low-dose Leucovorin (Mayo Clinic regimen - LDLV) in colon cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==5-FU & low-dose Leucovorin (Mayo Clinic regimen/LDLV)==
Original references may be found at 5-FU & low-dose Leucovorin (Mayo Clinic regimen/LDLV) (adjuvant) & 5-FU & low-dose Leucovorin (Mayo Clinic regimen/LDLV) (metastatic)
===Example regimen #1===
*Folinic acid (Leucovorin) 20 mg/m2 IV over 15 to 30 minutes on days 1 to 5, given first before 5-FU 
*Fluorouracil (5-FU) 425 mg/m2 IV push on days 1 to 5, given after leucovorin
28-day cycles x 6 cycles for adjuvant therapy; in metastatic settings, given until progression of disease or unacceptable toxicity
====Supportive medications====
*Prochlorperazine (Compazine) 10 mg PO once; 30 minutes prior to chemotherapy
Hydration:
*500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
*Hold if ANC <1000 and platelets <100 and notify physician.
Category:Example chemotherapy order sets
Example orders for ABVD in Hodgkin lymphoma

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==ABVD==
ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
Original references may be found at ABVD
===Example regimen #1===
*Doxorubicin (Adriamycin) 25 mg/m2 IV on days 1 & 15
**Given as IV push through running IV.
*Bleomycin (Blenoxane) 10 units/m2 IV on days 1 & 15 
**For cycle 1 only: Bleomycin (Blenoxane) 1 unit test dose infused over 15 minutes. Observe patient for 60 minutes prior to administering the remainder of the full dose.
**Infuse over 30 minutes after premedication with acetaminophen (Tylenol).
*Vinblastine (Velban) 6 mg/m2 IV on days 1 & 15
**Given as IV push through running IV. 
*Dacarbazine (DTIC) 375 mg/m2 IV on days 1 & 15
**Given over 60 minutes, with rate adjustments as needed based on patient tolerability. 
28-day cycles x 6 cycles
====Supportive therapy====
*Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to chemotherapy
*Diphenhydramine (Benadryl) 25 mg PO once; 30 minutes prior to chemotherapy
*Ondansetron (Zofran) 8 mg PO once; 30 minutes prior to chemotherapy 
*Aprepitant (Emend) 125 mg PO on days 1 & 15, 80 mg PO on days 2 to 3, 16-17
*Dexamethasone (Decadron) 4 mg PO twice per day on days 1 to 3, 15-17
Hydration:
*500 ml NS and/or D5W at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS and/or D5W as needed for IV compatibility.
Monitoring:
*On day 1 & 15 of each cycle: CBC with differential, absolute neutrophil count (ANC), comprehensive metabolic panel (including chem 10 & liver function tests (LFTs), LDH, uric acid
*Physician to be notified if LFTs/bilirubin are outside normal limits, ANC less than 1000, platelets less than 100.
*Check pulmonary function test (PFTs) with DLCO (diffusing capacity of the lung for carbon monoxide) prior to starting therapy and after 3-4 cycles of therapy. May perform PFTs as soon as after 2 cycles in high risk patients, such as recent smokers.
*Smoking cessation for smokers given risk of bleomycin pulmonary toxicity.
*Echocardiogram prior to start of therapy.
*Restage with PET/CT after 3 cycles of therapy.
Outpatient medications:
*Aprepitant (Emend) & Dexamethasone (Decadron) as described above in Supportive medications.
*Trimethoprim/Sulfamethoxazole (Bactrim SS) 80/400 mg PO daily for PCP prophylaxis
*Ondansetron (Zofran) 8 mg PO three times per day prn nausea
*Prochlorperazine (Compazine) 10 mg PO every 6 hours prn nausea
Clinical scenario & comments:
*28 year-old gentleman with stage IIIAs Hodgkin lymphoma, treated with 6 cycles of ABVD.
Category:Example chemotherapy order sets
Example orders for CHOEP in lymphoma

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==CHOEP, CHOPE==
CHOEP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Etoposide, Prednisone
Published regimens and references may be found on the Aggressive Non-Hodgkin lymphoma page. 
===Example regimen #1===
*Cyclophosphamide (Cytoxan) 750 mg/m2 IV on day 1
*Doxorubicin (Adriamycin) 50 mg/m2 IV on day 1
*Vincristine (Oncovin) 2 mg IV on day 1
*Etoposide (Vepesid) 100 mg/m2 IV on days days 1-3
*Prednisone (Sterapred) 100 mg PO on days 1 to 5
*Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 3600 cGy radiation therapy and to extranodal sites of disease when possible
21-day cycles x 6 cycles
====Supportive therapy====
*Fosaprepitant (Emend injection) 150 mg IV x1 on day 1 prior to chemotherapy
*Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy 
*Allopurinol (Aloprim) as described below
Hydration:
*500 ml NS and/or D5W KVO rate to be used as running IV for chemotherapy infusion. Give up to 500 ml NS and/or D5W.
Monitoring:
*On days 1, 3, 8, and 17 of cycle 1: CBC with differential, absolute neutrophil count (ANC), comprehensive metabolic panel (chem 10 and LFTs), LDH, uric acid; future labs to be determined based on patient's cycle 1 counts
*Prior to start of therapy, check beta-2 microglobulin, SPEP, IgG, IgA, IgM 
*Initial staging with CT torso & bone marrow biopsy
*In anticipation of rituxan use starting cycle 2, check hepatitis B surface antibody (HbsAb), hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb), hepatitis C antibody (HCV Ab)
Outpatient medications:
*Acyclovir (Zovirax) 400 mg PO three times per day
*Allopurinol (Aloprim) 300 mg PO daily
*Filgrastim (Neupogen) 300 mcg (patient is 63 kg) SC daily on days 4-13 
*Ondansetron (Zofran) 8 mg PO three times per day
*Pantoprazole (Protonix) 40 mg PO daily
*Prednisone (Sterapred) as described above
*Docusate (Colace) 100 mg PO twice per day prn constipation
*Sennosides (Senna) 8.6 mg PO every 8 hours prn constipation
Clinical scenario & comments:
*44 year-old lady with primary mediastinal lymphoma; 7 cm anterior mediastinal mass, ECOG performance status 0.
Category:Example chemotherapy order sets
Example orders for CapeOx (XELOX) in colon cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==CapeOx (XELOX)==
CapeOX: Capecitabine, OXaliplatin 
XELOX: XELoda, OXaliplatin
Published regimens and references may be found on the colon cancer page.
===Example regimen #1===
*Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
*Oxaliplatin (Eloxatin) 130 mg/m2 IV over 2 hours on day 1
**Mix in 500 mL D5W, and only infuse through D5W line.
21-day cycles x 8 cycles for adjuvant therapy; in metastatic settings, given until progression of disease or unacceptable toxicity
====Supportive therapy====
*Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy 
*Dexamethasone (Decadron) 10 mg IV 30 minutes prior to chemotherapy
*Calcium gluconate 1 g & magnesium sulfate 1 g (admixed together) IV, given over 30 minutes, to start prior to oxaliplatin to decrease likelihood of neuropathy
*Calcium gluconate 1 g & magnesium sulfate 1 g (admixed together) IV, given over 30 minutes, to start after oxaliplatin infusion is complete to decrease likelihood of neuropathy
*Calcium and magnesium no longer recommended to reduce risk of oxaliplatin-induced neuropathy: Charles L. Loprinzi, Rui Qin, Shaker R. Dakhil, Louis Fehrenbacher, Philip J. Stella, Pamela J. Atherton, Drew K. Seisler, Rubina Qamar, Grant Carlton Lewis, Axel Grothey. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study. 2013 ASCO Annual Meeting abstract 3501. link to abstract
Hydration:
*500 ml D5W at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml D5W.
Monitoring:
*Hold if ANC less than 1000 or platelets less than 100 and notify physician.
Comments:
*My institution uses the schedule described by Haller et al. 2011.
Category:Example chemotherapy order sets
Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==Carboplatin (Paraplatin) & Pemetrexed (Alimta)==
Original references may be found at Carboplatin (Paraplatin) & Pemetrexed (Alimta)
===Example regimen #1===
*Carboplatin (Paraplatin) AUC 5 IV on day 1
**Infuse over 30-60 minutes.
*Pemetrexed (Alimta) 500 mg/m2 IV on day 1
**Administer over 10 minutes. Administer after carboplatin.
21-day cycles x 6 cycles
====Supportive therapy====
*Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy 
*Lorazepam (Ativan) 0.5-1 mg IV or PO x 1 prn nausea/anxiety 
*Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea 
*Dexamethasone (Decadron) 4 mg PO twice per day the day before, day of, and day after chemotherapy
*Cyanocobalamin (Vitamin B12) 1000 mcg IM every 9 weeks, the first dose given at least 1 week prior to start of pemetrexed therapy
*Folic acid 1000 mcg PO daily, to start at least 1 week prior to start of pemetrexed therapy, to continue throughout therapy with pemetrexed
Hydration:
*500 ml NS and/or D5W at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS and/or D5W as needed for IV compatibility.
Monitoring:
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr as part of a basic metabolic panel, alk phos, AST, ALT, total bilirubin, albumin, carcinoembryonic antigen
**Depending on provider preference and patient's tolerance, may simplify to CBC with differential, absolute neutrophil count (ANC), BUN/Cr
*On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
*Assess for response with CT scan after cycle 3
Outpatient medications:
*Dexamethasone (Decadron) as described above
*Lorazepam (Ativan) 0.5 mg PO every 6 hours prn anxiety, insomnia, nausea
*Ondansetron (Zofran) 4 mg PO every 6 hours prn nausea
*Prochlorperazine (Compazine) 10 mg PO every 6 hours prn nausea 
*Folic acid 1000 mcg PO daily as described above
*Due to refractory nausea, in later cycles, we eventually added Aprepitant (Emend) 125 mg PO on day 1, 80 mg PO on days 2 to 3, and Dexamethasone (Decadron) use was extended to include day -1 through day 4
Clinical scenario & comments:
*60 year-old lady with stage IV adenocarcinoma of the lung, treated with first-line therapy for metastatic disease. Our institution's standard order set uses Carboplatin (Paraplatin) at AUC 5. This is reasonable in my view; the patient also had a history of pelvic radiation and chemotherapy for an unrelated malignancy many years ago. This was subsequently followed by Pemetrexed (Alimta) maintenance therapy.
Category:Example chemotherapy order sets
Example orders for Cetuximab (Erbitux) in colon cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==Cetuximab (Erbitux)==
Original references may be found at Cetuximab (Erbitux)
===Example regimen #1===
For cycle 1:
*Cetuximab (Erbitux) 400 mg/m2 IV over 2 hours on day 1
**Use non-DEHP/paclitaxel tubing.
*Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 8, 15, 22
**Use non-DEHP/paclitaxel tubing.
28-day cycle
====Supportive therapy====
*Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab 
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab 
Hydration:
*500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
*Hold if ANC less than 1000 or platelets less than 100 and notify physician.
For cycle 2 and later:
*Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 1, 8, 15, 22
**Use non-DEHP/paclitaxel tubing.
28-day cycles
====Supportive therapy====
*Acetaminophen (Tylenol) 650 mg PO once; 30 minutes prior to cetuximab 
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to cetuximab 
Hydration:
*500 ml NS at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
*Hold if ANC less than 1000 or platelets less than 100 and notify physician.
Comments:
*My institution uses 28-day cycles for Cetuximab (Erbitux) regimens.
Category:Example chemotherapy order sets
Example orders for Dacarbazine (DTIC) in melanoma

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==Dacarbazine (DTIC)==
Published regimens and references can be found on the melanoma page.
===Example order set #1===
*Dacarbazine (DTIC) 1000 mg/m2 IV over 60 to 90 minutes once on day 1
21-day cycles
====Supportive therapy====
*Ondansetron (Zofran) 8 mg IV once; 30 minutes prior to chemotherapy
Hydration:
*Normal saline IV continuous infusion at 5 mL/H
*Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
*Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete. 
*Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.
Category:Example chemotherapy order sets
Example orders for Degarelix (Firmagon) in prostate cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==Degarelix (Firmagon)==
Published regimens and references can be found on the prostate cancer page.
===Example order set #1===
====Loading dose====
*Degarelix (Firmagon) 240 mg SC once on day 1. Give as two 120 mg injections with a 27 gauge, 1 1/4 inch needle. Administer at a 45 degree angle SC into the periumbilical tissue while holding the tissue in a tented up fashion. 
start maintenance doses 28 days after loading dose
====Maintenance doses====
*Degarelix (Firmagon) 80 mg SC once on day 1. Give as one 80 mg injection with a 27 gauge, 1 1/4 inch needle. Administer at a 45 degree angle SC into the periumbilical tissue while holding the tissue in a tented up fashion. 
28-day cycles
Category:Example chemotherapy order sets
Example orders for Docetaxel & Carboplatin in prostate cancer

Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
==Docetaxel & Carboplatin==
Published regimens and references can be found on the prostate cancer page.
===Example order set #1===
*Docetaxel (Taxotere) 60 mg/m2 IV over 60 minutes once on day 1; use non-DEHP (paclitaxel) tubing
*Carboplatin (Paraplatin) AUC 4 IV once over 30 to 60 minutes once on day 1
21-day cycles
====Supportive therapy====
*Dexamethasone (Decadron) 8 mg PO given twice, the evening before and morning of chemotherapy 
*Dexamethasone (Decadron) 12 mg PO once; 30 minutes prior to chemotherapy
*Ondansetron (Zofran) 8 mg PO once; 30 minutes prior to chemotherapy
Hydration:
*Normal saline IV continuous infusion at 5 mL/H
*Normal saline 25 to 50 mL IV prn flush before and after chemotherapy
Nursing:
*Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete. 
*Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.
Category:Example chemotherapy order sets